Brief: InflaRx Announces Positive Topline Results from Multiple Ascending Dose Phase I Study with C5aR Inhibitor INF904
04/01/2024 12:36
Jan 4 (Reuters) - InflaRx NV IF0G.F :
* INFLARX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE
MULTIPLE
ASCENDING DOSE (MAD) PHASE I STUDY WITH C5AR INHIBITOR INF904
* INFLARX NV: WELL TOLERATED WITH NO SAFETY SIGNALS OF
CONCERN
OVER ENTIRE DOSE RANGE
* INFLARX NV: ACHIEVED FAVORABLE CONCENTRATION-TIME PROFILES
WITH
TARGET EXPOSURES OF THERAPEUTIC POTENTIAL
* INFLARX NV: INFLARX PLANS TO BRING INF904 INTO CLINICAL
PHASE II
DEVELOPMENT TOWARDS END OF 2024
Source text for Eikon: ID:nGNX6nWtDG
Further company coverage: IF0G.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum